A novel deep learning prognostic system improves survival predictions for stage III non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4782
Abstract: Accurate prognostic prediction plays a crucial role in the clinical setting. However, the TNM staging system fails to provide satisfactory individual survival prediction for stage III non‐small cell lung cancer (NSCLC). The performance of the… read more here.
Keywords: non small; iii non; stage iii; small cell ... See more keywords
Real‐world KINDLE‐Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non‐small‐cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4990
Abstract: Stage III non‐small‐cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real‐world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from… read more here.
Keywords: non small; iii non; stage iii; small cell ... See more keywords
Keys to successful induction chemoradiotherapy followed by surgery for stage III/N2 non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Surgery Today"
DOI: 10.1007/s00595-019-1766-8
Abstract: Surgical intervention after induction chemoradiation is designed as curative treatment for resectable stage III/N2 non-small cell lung cancer. However, there is no definitive evidence to support this approach, possibly because successful treatment requires certain “arts”,… read more here.
Keywords: stage iii; rate; non small; induction ... See more keywords
Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Radiation Oncology"
DOI: 10.1016/j.adro.2020.10.027
Abstract: Background Radiation with platinum-based chemotherapy is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). Despite aggressive treatment, progression-free survival and overall survival remain poor. It is unclear whether any tumor… read more here.
Keywords: stage iii; response; non small; chemoradiation ... See more keywords
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Cancer"
DOI: 10.1038/s41416-020-01070-6
Abstract: When treating patients with unresectable stage III non-small-cell lung cancer (NSCLC), those with a good performance status and disease measured within a radical treatment volume should be considered for definitive concurrent chemoradiotherapy (cCRT). This guidance… read more here.
Keywords: stage iii; treatment; non small; cancer ... See more keywords
Influence of poling angle on a mode-III non-centric semi-permeable crack in the piezoelectric strip under linearly varying load over developed zones
Sign Up to like & getrecommendations! Published in 2021 at "Mechanics of Advanced Materials and Structures"
DOI: 10.1080/15376494.2021.1953647
Abstract: The influence of changing poling angle on mode-III non-centric semi-permeable straight hairline crack in an infinitely long piezoelectric strip under small-scale electric yielding is studied. The d... read more here.
Keywords: centric semi; angle mode; non centric; poling angle ... See more keywords
Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14218
Abstract: This study aimed to establish a predictive nomogram integrating epidermal growth factor receptor (EGFR) mutation status for 3‐ and 5‐year overall survival (OS) in unresectable/inoperable stage III non‐small cell lung cancer (NSCLC) treated with definitive… read more here.
Keywords: cancer; iii non; survival unresectable; small cell ... See more keywords
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14667
Abstract: Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer (NSCLC). Given the heterogeneity of stage III NSCLC patients, in this study we evaluated the… read more here.
Keywords: non small; iii non; stage iii; small cell ... See more keywords
Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
Sign Up to like & getrecommendations! Published in 2023 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14780
Abstract: Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non‐small‐cell lung cancer based on the results of the PACIFIC trial. Based on trial criteria, not all patients are eligible for durvalumab in routine… read more here.
Keywords: non small; iii non; stage iii; small cell ... See more keywords
Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.680615
Abstract: Purpose For resectable cases of stage III-N2 non-small cell lung cancer (NSCLC), the best treatment after surgery is still uncertain. The effect of postoperative radiotherapy (PORT) is controversial. Thus, we performed this updated meta-analysis to… read more here.
Keywords: stage iii; analysis; port; non small ... See more keywords
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.904800
Abstract: Objectives To compare the rate disparity between outcomes (overall survival (OS), progression-free survival (PFS), and safety) of concurrent chemoradiation (cCRT) followed by durvalumab in two patient cohorts with locally advanced (LA) stage III non-small cell… read more here.
Keywords: non small; iii non; stage iii; small cell ... See more keywords